Rose Stokes, a 37-year-old mother, experienced a severe mental health crisis while overlooking the Bath skyline on Good Friday 2025. The relapse of her postnatal depression and anxiety followed her decision to begin taking the weight-loss drug Mounjaro.
The New Year's Eve transition to tirzepatide
Rose Stokes's experience suggests a complex interplay between hormonal shifts and new pharmaceutical interventions during the postpartum period. After finishing breastfeeding, the mother began taking tirzepatide,a GLP-1 agonist marketed under the brand name Mounjaro, around the end of 2024. as the report indicates, the medication initially caused rapid weight loss and a sense of euphoria, but these effects were soon overshadowed by a profound mental health decline.
The timing of the medication use coincided with a significant life transition for Stokes. According to the account shared by Stokes, she began the tirzepatide regimen just a few days after Christmas, noting that her appetite vanished almost immediately. While the weight loss was rapid, the psychological stability she had maintained during the first six months of her second son's life began to erode shortly after the New Year.
A terrifying breakdown overlooking the Bath skyline
Physical and psychological distress reached a breaking point for Stokes during a family outing in early 2025. While pushing a double buggy up a steep slope near a lake, she experienced a moment of such intense despair that she told her husband, Simon, she believed her family would be better off without her. this crisis occurred on the grounds of a stately home overlooking the skyline of Bath.
The symptoms of this relapse were both sudden and physically overwhelming. Stokes reported feeling completely disconnected from her surroundings during social interactions, such as a coffee morning with friends. She described experiencing a racing heart and profuse sweating, marking a sharp departure from the relative stability she had enjoyed as a second-time parent.
A history of mental health struggles since her first son
This recent crisis is an echo of a previous battle with postnatal depression and anxiety that began after the birth of Stokes's first son. During her first experience with postpartum mental health issues,she described feeling a profound sense of worthlessness and shame. This history made the couple cautious when preparing for their second child, ensuring they had a support network in place.
The contrast between her two experiences highlights how much her mental health had improved prior to the introduction of Mounjaro. For the first six months following her second son's birth, Stokes felt relieved to be free of depression, bolstered by therapy and her growing confidence as a parent. The suddenness of the relapse suggests that the introduction of new medication may have disrupted this hard-won stability .
The unproven connection between tirzepatide and mental health
Medical experts have yet to confirm if there is a direct causal relationship between Mounjaro and the onset of postnatal depression. While the report highlights the temporal link between Stokes starting tirzepatide and her subsequent relapse, it does not provide clinical data to prove the drug was the primary driver. It remains unclear how many other mothers might experience similar neuropsychiatric symptoms when transitioning from breastfeeding to GLP-1 agonists.
The story leaves several critical questions for healthcare providers and researchers. It is currently unknown whether the rapid weight loss associated with tirzepatide affects postpartum hormonal balance, or if the medication directly impacts neurotransmitters related to mood. For now, organizations like the National Childbirth Trust and Mind remain vital resources for mothers navigating these unpredictable mental health waters.
Comments 0